British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently
entered a definitive agreement to provide its patented DehydraTECH(TM)
technology to Cannadips CBD. An article discussing the company reads, “The
agreement announced recently provides Cannadips CBD with exclusive access
rights to Lexaria’s technology for the U.S. market for 10 years, granting the
‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption
technology with options to expand the license to Europe, Mexico, and Canada and
to renew the license for an additional five years (http://ibn.fm/8hoPO). . . . ‘This combination of superior
science from Lexaria and a unique and strong branded proposition that Cannadips
offers with its CBD pouch platform is a winning combination. We are excited to
be developing a category of products with best-in-class science to provide
adult consumers the simple choice of a better product and a better alternative
to tobacco and nicotine,’ Lexaria board member Brian Quigley, who is also an
adviser to The Boldt Runners Corporation (Cannadips), stated in a news
release.”
To view the full article, visit http://ibn.fm/cxOZx
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a licensed,
in-house research laboratory and holds a robust intellectual-property portfolio
with 16 patents granted and over 60 patents pending worldwide. For more
information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment